Comparative Study of Sequential Combinations of Paclitaxel and Methotrexate on a Human Bladder Cancer Cell Line

References

• American Cancer Society. Cancer Facts and Figures—1993. American Cancer Society, Atlanta 1993; 12–18
   Google Scholar
• Feldman A R, Kessler L, Myers M H. The prevalence of cancer: estimates based on the Connecticut Tumor Registry. N Engl J Med 1986; 315: 1394–1397
   PubMed Web of Science ®Google Scholar
• Schiff P B, Fant J, Horwitz S B. Promotion of microtuble assembly in vitro by paclitaxcel. Nature 1979; 277: 665–667
   PubMed Web of Science ®Google Scholar
• Schiff P B, Horwitz S. Paclitaxel stabilizes microtubules in mouse fibroblast cells. Proc Natl Acd Sci USA 1980; 77: 1561–1565
   PubMed Web of Science ®Google Scholar
• Kumar N. Paclitaxel-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 1981; 256: 10435–10441
   PubMed Web of Science ®Google Scholar
• McGuire W P, Rowinsky E K, Rosenshein N B. Taxol: a unique antineoplastic agent with significant activity in advanced epithelial neoplasms. Ann Intern Med 1993; 273–279
   Google Scholar
• Holmes F A, Walters R S, Theriault R L. Phase II trial of Taxol and active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797–1805
   PubMed Web of Science ®Google Scholar
• Chang A, Kim K, Glick J. Phase II study of taxol in patients with stage IV non-small cell lung cancer (NSCLC): The Eastern Cooperative Oncology Group (ECOG) results. Proc Am Soc Clin Oncol 1992; 11: 293, abstract
   Google Scholar
• Forastiere A A. Use of paclitaxel (taxol) in squamous cell carcinoma of the head and neck. Semin Oncol 1993; 20: 56–60
   PubMed Web of Science ®Google Scholar
• Allegra C J, Fine R L, Drake J C. The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells: evidence for direct inhibition of purine synthesis. J Biol Chem 1986; 261: 6478–6485
   PubMed Web of Science ®Google Scholar
• Fernandes D J, Sur P, Kute T E. Proliferation-dependent cy totoxicity of methotrexate in murine L5718Y leukemia. Cancer Res 1988; 48: 5638–5644
   PubMed Web of Science ®Google Scholar
• Ross C A, Selawry O S. Comparison of doses of intermittent methotrexate in lung cancer. Am Assoc Cancer Res 1966; 7: 60
   Google Scholar
• Schmiegelow K, Schroder H, Schmiegelow M. Methotrexate and 6-mercaptopuringe maintenance therapy for childhood acute lymphoblastric leukemia: dose adjustments by white cell counts or by pharmacokinetic parameters. Cancer Chemother Pharmacol 1994; 343: 209–215
   Google Scholar
• Bellmunt J, Ribas A, Albanell J. Preliminary results of a phase II randomized controlled trial comparing M-VAC and MCAVI in patients with bladder cancer (T2–4 NO-1 MO). Arch Esp Urol 1996; 49: 465–472
   PubMedGoogle Scholar
• Bellmunt J, Ribas A, Albanell J. M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2–4NOMO carcinoma of the bladder. Am J Clin Oncol 1996; 19: 344–348
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Ribas A, Eres N. Carboplatin-based versus cis-platin-based chemotherapy in the treatment of surgical incurable advanced bladder carcinoma. Cancer 1966–1972; 80, 1997
   Google Scholar
• Roth B J. Chemotherapy for advanced bladder cancer. Semin Oncol 1996; 23: 633–644
   PubMed Web of Science ®Google Scholar
• Witte R, Loehrer P, Dreicer R. Ifosfamide (IFX) in advanced urothelial carcinoma: an ECOG trial. Proc Am Soc Clin Oncol 1993; 12: 23, abstract
   Google Scholar
• Seligman P A, Crawford E D. Treatment of advanced transitional cell carcinoma of the bladder with continuous infusion gallium nitrate. J Natl Cancer Inst 1991; 83: 1582–1584
   PubMed Web of Science ®Google Scholar
• Roth B J, Dreicer R, Einhorn L H. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994; 12: 2264–2270
   PubMed Web of Science ®Google Scholar
• Rowinsky E K. The taxanes: dosing and scheduling considerations. Oncology 1997; 11(3 Suppl 2)7–19
   PubMedGoogle Scholar
• Aisner J, Cortés-Funes H. Paclitaxel in head and neck and other cancer: future prospects. Semin Oncol 1997; 24: S2–113–S2–115, 1 Suppl 2
   Google Scholar
• Berenbaum M C. Synergism, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol 1977; 28: 1–18
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Hartmann J T, Kuczyk M A. The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors. World J Urol 1996; 14: 354–359
   PubMed Web of Science ®Google Scholar
• Rowinsky EDonehower K. RC., Jones R J. Microtubule changes and cytotoxicity in leukemic cell linestreatcd with taxol. Cancer Res 1988; 48: 4093–4100
   PubMed Web of Science ®Google Scholar
• Nygren P, Csoka K, Jonsson B. The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL. Br J Cancer 1995; 71: 478–481
   PubMed Web of Science ®Google Scholar
• Eisenhauer E A, Ten Bokkel Huinink W W, Swenerton K D. European-Canadian randomozed trial of paclitaxel in relapsed ovarian cancer: high dose versus low dose and long versus short infusion. J Clin Oncol 1994; 12: 2654–2666
   PubMed Web of Science ®Google Scholar
• Liebmann J E, Cook J A, Lipsschultz C. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 1993; 68: 1104–1109
   PubMed Web of Science ®Google Scholar
• Rangel C, Niell H, Miller A. Taxol and taxotere in bladder cancer: in vitr activity and urine stability 1994; 33: 460–464
   Google Scholar
• Chou T C, Otter G M, Sirotnak F M. Combined effects of edatrexate with taxol or taxotere against breast cancer cell growth. Proc Am Assoc Cancer Res 1993; 34: 3000, abstract
   Google Scholar
• Chabner B A, Collins J A. Cancer Chemotherapy. Principles and Practice. Lippincott, Philadelphia 1990
   Google Scholar
• Lorico A, Toffoli G, Boiocchi M. Accumulation of DNA strand breacks in cells exposed to Methotrexate or N10-propargyl-5,8-dideazafolic acid. Cancer Res 1988; 48: 2036–2041
   PubMed Web of Science ®Google Scholar
• Brochers A H, Kennedy D A, Straw J A. Inhibition of DNA excision repair by methotrexate in Chinese ovary cells following exposure to ultraviolet irradiation or ethylmethane sulfonate. Cancer Res 1990; 43: 5217–5221
   Google Scholar
• Milross G, Mason K A, Hunter N R. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88 1996; 18: 1308–1314
   Google Scholar
• Pletjushkina O J, Ivanova O J, Kaverina I N. Taxol-trated fi-broblasts acquire an epithelioid shape and a circular pattern of actin bundles. Exp Cell Res 1994; 212(2)201–208
   PubMed Web of Science ®Google Scholar
• Chen C S, Mrksich M, Huang S. Geometric control of cell life and death. Science 1997; 276: 1425–1428
   PubMed Web of Science ®Google Scholar
• Frankel A, Buckman R, Kerbel R S. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res 1997; 57: 2388–2393
   PubMed Web of Science ®Google Scholar